KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Revenue (2017 - 2025)

Historic Revenue for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $784.5 million.

  • Amneal Pharmaceuticals' Revenue rose 1167.95% to $784.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 billion, marking a year-over-year increase of 949.62%. This contributed to the annual value of $2.8 billion for FY2024, which is 1672.58% up from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Revenue of $784.5 million as of Q3 2025, which was up 1167.95% from $724.5 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Revenue registered a high of $784.5 million during Q3 2025, and its lowest value of $493.1 million during Q1 2021.
  • For the 5-year period, Amneal Pharmaceuticals' Revenue averaged around $615.7 million, with its median value being $609.8 million (2022).
  • Its Revenue has fluctuated over the past 5 years, first plummeted by 108.88% in 2021, then surged by 1840.2% in 2024.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Revenue stood at $536.9 million in 2021, then increased by 13.57% to $609.8 million in 2022, then grew by 1.18% to $617.0 million in 2023, then grew by 18.4% to $730.5 million in 2024, then increased by 7.39% to $784.5 million in 2025.
  • Its last three reported values are $784.5 million in Q3 2025, $724.5 million for Q2 2025, and $695.4 million during Q1 2025.